Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 14/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514687 | 0.84 | BRD4 (0.49) | LTA4HHDAC4HPGDSKDM4E | |
| SCHEMBL18016065 | 0.84 | LTA4H (0.47) | LTA4HHDAC4HPGDS | |
| SCHEMBL5789925 | 0.84 | MKNK2 (0.51) | LTA4HNPC1RAB9AHDAC4HPGDS | |
| SCHEMBL722557 | 0.82 | LTA4H (0.64) | LTA4HHDAC4HPGDS | |
| SCHEMBL939928 | 0.80 | KEAP1 (0.55) | LTA4HNPC1RAB9AHPGDSKDM4E | |
| SCHEMBL31558442 | 0.80 | KEAP1 (0.55) | LTA4HNPC1RAB9AHPGDSKDM4E | |
| SCHEMBL3349057 | 0.80 | GLRA3 (0.60) | LTA4HNPC1RAB9AHDAC4KDM4E | |
| SCHEMBL28362996 | 0.80 | LTA4H (0.62) | LTA4HHDAC4HPGDS | |
| SCHEMBL28257875 | 0.80 | LTA4H (0.62) | LTA4HHDAC4HPGDS | |
| SCHEMBL28320605 | 0.80 | LTA4H (0.62) | LTA4HHDAC4HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110407763-B | Synthesis method of 4- (oxazole-2-yl) benzoic acid | 苏州汉德创宏生化科技有限公司 | 2022-10-14 | — | — | CN | claimed |
| EP-4559902-A2 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3256218-B1 | A KDM1A INHIBITOR AND ITS USE IN THERAPY | IMAGO BIOSCIENCES INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-110407763-B | Synthesis method of 4- (oxazole-2-yl) benzoic acid | 苏州汉德创宏生化科技有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-110407763-B | Synthesis method of 4- (oxazole-2-yl) benzoic acid | 苏州汉德创宏生化科技有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-110407763-B | Synthesis method of 4- (oxazole-2-yl) benzoic acid | 苏州汉德创宏生化科技有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-20220073477-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| CN-1759095-A | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARM INC (US) | 2006-04-12 | — | — | CN | disclosed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | disclosed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073477-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | LTA4H 4251/4885NPC1 4418/4885RAB9A 3635/4885 |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | LTA4H 3001/4885NPC1 763/4885RAB9A 1302/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | LTA4H 4251/4885NPC1 4418/4885RAB9A 3635/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | LTA4H 1941/4885NPC1 593/4885RAB9A 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.